TY  - CHAP
M1  - Book, Section
TI  - Endocrine and Metabolic Complications of Cancer Therapy
A1  - Hosein, Rachael
A1  - Bedrose, Sara
A1  - Jeun, Rebecca
A1  - Varghese, Jeena M.
A1  - Thosani, Sonali N.
A2  - Kantarjian, Hagop M.
A2  - Wolff, Robert A.
A2  - Rieber, Alyssa G.
Y1  - 2022
N1  - 
T2  - The MD Anderson Manual of Medical Oncology, 4e
AB  - KEY  CONCEPTSImmune  checkpoint  inhibitors  have  become  mainstays  of  therapy  for  a  broad  range  of  cancers  and  can  lead  to  a  variety  of  endocrinopathies,  including  hypophysitis,  thyroiditis,  primary  hypothyroidism,  Graves  disease,  primary  adrenal  insufficiency,  lipodystrophy,  and  autoimmune  diabetes.A  broad  range  of  antineoplastic  agents,  including  agents  that  target  the  phosphoinositide  3-kinase  (PI3K)/Akt/mammalian  target  of  rapamycin  (mTOR)  pathway  and  tyrosine  kinase  inhibitors  (TKIs),  alter  glucose  homeostasis  and  can  lead  to  hyperglycemia,  which  may  require  monitoring  and  treatment.Hormone-suppressive  therapies,  radiation  treatments,  chemotherapeutics,  and  corticosteroids  can  all  lead  to  increased  bone  fragility,  which  may  be  ameliorated  by  antiresorptive  agents  such  as  bisphosphonates  or  denosumab.Patients  who  receive  cranial  or  craniospinal  radiation  therapy  are  at  risk  for  hypothalamic  and  pituitary  dysfunction,  and  those  who  receive  radiation  to  the  head  and  neck  or  other  sites  close  to  the  thyroid  are  at  risk  for  hypothyroidism  and  thyroiditis.Cytotoxic  chemotherapy  and  radiation  therapy  are  common  causes  of  hypogonadism  and  infertility  in  both  male  and  female  cancer  survivors  and  should  be  discussed  with  patients  before  initiation  of  therapy.Childhood  cancer  survivors,  especially  those  who  received  abdominal  radiation  or  total-body  irradiation,  are  at  increased  risk  of  diabetes  mellitus  and  metabolic  syndrome  as  long-term  sequelae  of  cancer  treatment  and  need  continued  follow-up  and  screening  for  these  conditions  in  survivorship  care.  
SN  - 
PB  - McGraw Hill Education
CY  - New York, NY
Y2  - 2024/04/24
UR  - hemonc.mhmedical.com/content.aspx?aid=1190839743
ER  -